Leading researcher and pioneer in biomarker development and use of functional imaging in chronic pain
REDMOND, WA, December 18, 2023 — Pattern Computer®, Inc. (“Pattern” or “the Company”) is pleased to announce that David Borsook, M.D. Ph.D., is joining the Company’s Advisory Board. A world-renowned clinician-scientist, Dr. Borsook previously held appointments at McLean Hospital, Massachusetts General Hospital (“MGH”), and Children’s Hospital Boston, Harvard Medical School, and currently is a Professor Emeritus in Anesthesiology at Harvard Medical School and holds appointments in the Departments of Psychiatry and Radiology at Massachusetts General Hospital. He received his training from the University of The Witwatersrand Medical School, South Africa, where he received the following degrees: BSc Biology, BSc (Honors) Physiology, MB BCh Medicine, and PhD Neurobiology; he has completed residencies in Neurology from Boston University Medical Center as well as Clinical/Research Fellowships at Brigham and Women’s Hospital, and Massachusetts General Hospital, Harvard Medical School.
As a leading researcher in the field of pain, Dr. Borsook has helped improve understanding of healthy and unhealthy neural pain networks in both human and animal models. He is a pioneer in the use of functional imaging in chronic pain, including migraine, and brain measure of analgesics in adults and children. Research by his group seeks to define brain biomarkers for disease state and treatment effects. Dr. Borsook established a research program investigating the use of functional magnetic resonance imaging (“fMRI”) in pain and analgesia with the support of the National Institutes of Health (“NIH”) and other nonprofit research foundations. He served on NCCAM Council at NIH and has been on a number of NIH groups related to future research in chronic pain and headache. He has over 350 peer-reviewed scientific publications and is the lead editor of 4 books, one on the use of imaging in central nervous system drug development that has been a representative on NIH-related think tanks in the field of pain. In addition, he holds numerous patents in the field of pain medicine and neuroimaging applications.
He previously held positions including co-founder and Chief Scientific Officer of Descartes Therapeutics, Inc., a biomedical startup that focused on biomarker development and the use of fMRI in drug development. He also helped take a drug he use-patented and licensed to Dara Biosciences for chronic pain at MGH through to a public listing. He now consults to a few biotech companies. In addition, Dr. Borsook has led efforts to try to establish research in biomarker development through consortia with pharmaceutical companies to emphasize the importance of biomarker testing, comprehensive genomic profiling, and identification of actionable targets across disease states. For example, he and his team have led a research program, now at MGH, in using a brain measure called functional near infrared spectroscopy to evaluate pain under anesthesia, a common process that may contribute to significant chronic pain post operatively.
“We are very pleased to have David join our team as an advisor,” said Mark R. Anderson, Chair and CEO of Pattern Computer. “We have assembled a team of world-class experts from across a multitude of disciplines, including mathematics, physics, computer science, data science, high performance computing, chemistry, bioinformatics, intellectual property, and corporate strategy. David’s expertise and insights in the commercialization and science of clinical practice will undoubtedly catalyze our initiatives, driving forward our research and development efforts in cancer biomarkers and drug discovery, potentially leading to innovative solutions and breakthroughs and adoption of our new combination cancer treatments. We look forward to benefitting from his experience and counsel.”
“I am excited to join the Pattern Computer Advisory Board,” commented Dr. Borsook. “The Company’s technology offers the potential to address a wide range of challenges presented in the management of chronic pain, a domain that lacks an equivalent of an antibiotic which has an associated specificity and sensitivity in its treatment profile. Objective measures of brain circuits could provide a fingerprint of specific behaviors, serving as a potential biomarker of disease state and analgesic drug effects. Defining a useful biomarker for chronic pain would allow for objective evaluation of pain treatments in clinical trials and in the clinic leading to potentially better treatment approaches, which would be an enormous advance. I believe my experience in clinical drug design and clinical trials may contribute to the Company achieving its strategic goals.”
About Pattern
Pattern Computer, Inc., a Seattle-area company, uses its proprietary Pattern Discovery Engine™ to solve the most important and intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.
As the Company applies its computational platform to the challenging fields of drug discovery and diagnostics, it is also making major Pattern Discoveries for partners in other sectors, including biotech, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance. www.patterncomputer.com.
CONTACT: Laura Guerrant-Oiye 808-960-2642 – laura@patterncomputer.com
The foregoing contains statements about Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.
Copyright © 2023 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine, PatternBio, TrueXAI, and ProSpectral are trademarks of Pattern Computer Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.